These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27249715)

  • 21. Peptide vaccines for the treatment of glioblastoma.
    Swartz AM; Batich KA; Fecci PE; Sampson JH
    J Neurooncol; 2015 Jul; 123(3):433-40. PubMed ID: 25491947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene therapeutics: the future of brain tumor therapy?
    Cutter JL; Kurozumi K; Chiocca EA; Kaur B
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):1053-64. PubMed ID: 16831077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunosuppressive mechanisms in glioblastoma.
    Nduom EK; Weller M; Heimberger AB
    Neuro Oncol; 2015 Nov; 17 Suppl 7(Suppl 7):vii9-vii14. PubMed ID: 26516226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological Aspects of Malignant Gliomas.
    Cohen-Inbar O; Zaaroor M
    Can J Neurol Sci; 2016 Jul; 43(4):494-502. PubMed ID: 27324313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Safety of available immunotherapy for the treatment of glioblastoma.
    Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
    Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.
    Ung N; Yang I
    J Neurooncol; 2015 Jul; 123(3):473-81. PubMed ID: 26070553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.
    Chistiakov DA; Chekhonin IV; Chekhonin VP
    Eur J Pharmacol; 2017 Sep; 810():70-82. PubMed ID: 28583430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How immunotherapies are targeting the glioblastoma immune environment.
    Felthun J; Reddy R; McDonald KL
    J Clin Neurosci; 2018 Jan; 47():20-27. PubMed ID: 29042147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma.
    Sinnadurai M; McDonald KL
    J Neurooncol; 2017 May; 132(3):359-372. PubMed ID: 28293764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.
    Mathios D; Park CK; Marcus WD; Alter S; Rhode PR; Jeng EK; Wong HC; Pardoll DM; Lim M
    Int J Cancer; 2016 Jan; 138(1):187-94. PubMed ID: 26174883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biomarkers and Immunotherapeutic Targets in Glioblastoma.
    Hung AL; Garzon-Muvdi T; Lim M
    World Neurosurg; 2017 Jun; 102():494-506. PubMed ID: 28300714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium.
    Kim ES; Kim JE; Patel MA; Mangraviti A; Ruzevick J; Lim M
    J Immunol Res; 2016; 2016():4683607. PubMed ID: 26881264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.
    Lucca LE; Hafler DA
    Immunol Rev; 2017 Mar; 276(1):9-25. PubMed ID: 28258696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Targeted therapy in glioblastoma: update and perspectives].
    Idbaih A; Duran-Peña A; Alentorn A
    Bull Acad Natl Med; 2015 Nov; 199(8-9):1323-1329. PubMed ID: 29874421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy and radiation in glioblastoma.
    Sahebjam S; Sharabi A; Lim M; Kesarwani P; Chinnaiyan P
    J Neurooncol; 2017 Sep; 134(3):531-539. PubMed ID: 28567588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glioblastoma antigen discovery--foundations for immunotherapy.
    Azad TD; Razavi SM; Jin B; Lee K; Li G
    J Neurooncol; 2015 Jul; 123(3):347-58. PubMed ID: 26045361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Present trend in the primary treatment of aggressive malignant glioma: glioblastoma multiforme.
    Parvez T
    Technol Cancer Res Treat; 2008 Jun; 7(3):241-8. PubMed ID: 18473496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in immunotherapy for the treatment of glioblastoma.
    Tivnan A; Heilinger T; Lavelle EC; Prehn JH
    J Neurooncol; 2017 Jan; 131(1):1-9. PubMed ID: 27743144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
    Maxwell R; Jackson CM; Lim M
    Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immunotherapy in brain tumors].
    De Carli E; Delion M; Rousseau A
    Ann Pathol; 2017 Feb; 37(1):117-126. PubMed ID: 28111040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.